NEW YORK – Fluidigm said on Wednesday that it will exclusively distribute antibodies from Bethyl Laboratories for use with Fluidigm's Imaging Mass Cytometry technology.
Bethyl Laboratories has a portfolio of more than 9,500 primary and secondary antibodies, including the recombinant monoclonal antibodies that are well-suited for imaging studies. Under the new agreement, antibody products manufactured by Bethyl will be verified on Fluidigm's Hyperion imaging system and subsequently offered to Fluidigm's customers.
Fluidigm currently offers more than 100 pathologist-verified metal‑conjugated Maxpar antibodies for use with imaging mass cytometry, including antibodies verified for use with both formalin-fixed paraffin-embedded (FFPE) and frozen tissues. These preconjugated antibodies enable researchers to obtain highly multiplexed images of a large number of sample types.
Fluidigm said the agreement with Bethyl will provide its customers access to a collection of antibodies that will increase in number over time and enable new research areas for imaging mass cytometry.
"Tools for understanding the immune system are more important than ever as researchers work to improve human health, particularly in responding to challenges posed by COVID‑19," Fluidigm CSO Andrew Quong said in a statement. "With Bethyl's leadership in specialized antibodies and our expertise in high-multiplex imaging technology, this collaboration will provide our customers with critically needed new research capabilities."